samedan logo
 
 
 
spacer
home > ebr > Summer 2020
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2020
   
Text
PDF
bullet
Analytical Methods
Risk Management for Analytical Method Development

Madalena R Testas, Daniela B Santos, and Josť C Menezes at 4Tune Engineering

In the biopharmaceutical industry, analytical methods are among the most critical elements for process monitoring and product release
 
view
download pdf
Beyond Big Data

Joern Klinger at biotx.ai

We canít always rely on Big Data to be available; therefore, itís worth suggesting ways of still effectively applying machine learning when thatís the case
 
view
download pdf
Genotoxic Impurities in Drug Products: Review of Nitrosamine Assays

Elodie Barrau, Emmanuel Desmartin, Valentina Paschetta, Davide Tartaglione, MÚnica Coll Furest, and Ana Novak at Eurofins

In the past couple of years, the prevalence of nitrosamines in drug substances has made them a hot topic of conversation in the medical industry
 
view
download pdf
bullet
R&D on COVID-19
The Quest for a Cure

David Wilson at Avacta

It's of little doubt that there is a great need for the development of rapid diagnostic tests to tackle the COVID-19 pandemic
 
view
download pdf
Leveraging Health Data to Support Patient Care

Gilles Paubert at Cegedim Health Data

There are some key areas where current real-world data can add immediate value to patients, the healthcare system, and our economies



 
view
download pdf
Would Greater Diversity and Inclusion Improve Innovation?


Stephen Frost at Frost Included

The pharma industry is responsible for great strides in world health, yet itís undeniable that there are still many more goals to accomplish, and a lack of diversity may be holding it back

 
view
download pdf
A Conversation with an Expert in Drug Development

As the world grapples with the impact of the COVID-19 pandemic, the life science industry and regulators are racing to find an effective treatment. We spoke with Colin Orford, Senior Vice President of Drug Development services at ICON plc about the direction that this work is taking
 
view
download pdf
bullet
Improving Drug Discovery Models
The Promise of Drug Discovery

The past few decades have seen large strides in the medical industry, but there are still many patients suffering with unmet medical needs that could benefit from further innovation, especially in drug discovery. EBR spoke to Dr Craig Fox, CSO at C4X Discovery, to ask about his thoughts on the subject

 
view
download pdf
Microphysiological Systems Emerging as Powerful Tools for Drug Discovery

Dr Audrey Dubourg at CN Bio

A new class of in vitro model is expected to assist drug discovery by providing robust physiologically relevant data at critical stages of R&D
 
view
download pdf
bullet
Features
Surfacing Missed Opportunities

David Gwyn at Amplexor

There are five areas in which richer, more holistic product information could shine a light into the life science industryís blind spots and help transform business outcomes
 
view
download pdf
Base Editing and Its Application to Cell and Gene Therapy

Dr Ceri Wiggins at Horizon Discovery

CRISPR-Cas gene editing has been a force to be reckoned with in gene engineering for years, and it doesnít seem likely this is going to change anytime soon


 
view
download pdf
Nova Biomedical FLEXģ2

With over 1,300 employees and manufacturing facilities in Waltham and Billerica, Massachusetts, and Taipei, Taiwan, Nova Biomedical is one of the 25 largest in vitro diagnostic companies in the world and the largest privately owned in vitro diagnostic company in the US
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

PPMA Show 2021 celebrates great success as it leads the way to build back business

The UKís largest processing and packaging machinery event returned to the NEC, Birmingham (28-30 September) following the cancellation of the 2020 Show. Hailed as a great success by exhibitors and visitors, over 250 exhibitors and 1,250 brands showcased the latest innovations in smart manufacturing, processing equipment and packaging solutions.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement